Retinopathy of prematurity

The Lancet

Volumn 382, Issue 9902, 2013, Pages 1445-1457

  Hellström, Ann ^a   Smith, Lois E H ^b,c   Dammann, Olaf ^d,e,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GLUCOSE; INSULIN; OXYGEN; PENICILLAMINE; PROPRANOLOL; SOMATOMEDIN C; VASCULOTROPIN;

ACADEMIC ACHIEVEMENT; AUSTRALIA AND NEW ZEALAND; AUSTRIA; BELGIUM; BIRTH WEIGHT; CAUSE OF DEATH; CEREBRAL PALSY; CHILDHOOD MORTALITY; COMORBIDITY; CONFERENCE PAPER; COST CONTROL; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENETIC POLYMORPHISM; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPEROXIA; INCIDENCE; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEWBORN DEATH; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NONHUMAN; NORWAY; OXYGEN SATURATION; OXYGEN TOXICITY; PATHOGENESIS; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; SCAR FORMATION; SMALL FOR DATE INFANT; SPECIAL EDUCATION; STRABISMUS; SWEDEN; TRANSPUPILLARY THERMOTHERAPY; WEIGHT GAIN;

EID: 84886246337     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60178-6     Document Type: Conference Paper

References (171)

1. Silverman WA. Retrolental fibroplasia: a modern parable. New York: Grune & Stratton, 1980.
2. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasias: a clinical approach. Med J Aust 1951; 2: 48-50.
3. Carlo WA, Finer NN, Walsh MC, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959-69.
4. Stenson B, Brocklehurst P, Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med 2011; 364: 1680-82.
5. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007; 10: 133-40.
6. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009; 24: 77-81.
7. Rivera JC, Sapieha P, Joyal JS, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011; 100: 343-53.
8. Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology 2011; 100: 116-29.
9. Mataftsi A, Dimitrakos SA, Adams GG. Mediators involved in retinopathy of prematurity and emerging therapeutic targets. Early Hum Dev 2011; 87: 683-90.
10. Lee J, Dammann O. Perinatal infection, infl ammation, and retinopathy of prematurity. Semin Fetal Neonatal Med 2012; 17: 26-29.
11. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012; 367: 2515-26.
12. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84.
13. Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C, GAPPS Review Group. Global report on preterm birth and stillbirth (1 of 7): defi nitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth 2010; 10 (suppl 1): S1.
14. Liu L, Johnson HL, Cousens S, et al, for the Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151-61.
15. Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmstrom GE. Incidence of retinopathy of prematurity in infants born before 27 weeks gestation in Sweden. Arch Ophthalmol 2009; 127: 1315-19.
16. Markestad T, Kaaresen PI, Ronnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115: 1289-98.
17. Allegaert K, de Coen K, Devlieger H, for the EpiBel Study group. Threshold retinopathy at threshold of viability: the EpiBel study. Br J Ophthalmol 2004; 88: 239-42.
18. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ, for the Australian and New Zealand Neonatal Network. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005; 115: 990-96.
19. Weber C, Weninger M, Klebermass K, et al. Mortality and morbidity in extremely preterm infants (22 to 26 weeks of gestation): Austria 1999-2001. Wien Klin Wochenschr 2005; 117: 740-46.
20. Tommiska V, Heinonen K, Lehtonen L, et al. No improvement in outcome of nationwide extremely low birth weight infant populations between 1996-1997 and 1999-2000. Pediatrics 2007; 119: 29-36.
21. Fledelius HC, Dahl H. Retinopathy of prematurity, a decrease in frequency and severity. Trends over 16 years in a Danish county. Acta Ophthalmol Scand 2000; 78: 359-61.
22. Lundqvist P, Kallen K, Hallstrom I, Westas LH. Trends in outcomes for very preterm infants in the southern region of Sweden over a 10-year period. Acta Paediatr 2009; 98: 648-53.
23. Haines L, Fielder AR, Scrivener R, Wilkinson AR, Pollock JI, for the Royal College of Paediatrics and Child Health, the Royal College of Ophthalmologists and British Association of Perinatal Medicine. Retinopathy of prematurity in the UK I: the organisation of services for screening and treatment. Eye (Lond) 2002; 16: 33-38.
24. Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005; 90: F240-44.
25. Holmstrom GE, Hellstrom A, Jakobsson PG, Lundgren P, Tornqvist K, Wallin A. Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol 2012; 130: 1418-24.
26. Tan SZ, Dhaliwal C, Becher JC, Fleck B. Trends in the incidence of retinopathy of prematurity in Lothian, south-east Scotland, from 1990 to 2009. Arch Dis Child Fetal Neonatal Ed 2012; 97: F310-11.
27. Hameed B, Shyamanur K, Kotecha S, et al. Trends in the incidence of severe retinopathy of prematurity in a geographically defined population over a 10-year period. Pediatrics 2004; 113: 1653-57.
28. Lad EM, Nguyen TC, Morton JM, Moshfeghi DM. Retinopathy of prematurity in the United States. Br J Ophthalmol 2008; 92: 320-25.
29. Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009; 148: 451-58.
30. Gunn DJ, Cartwright DW, Gole GA. Incidence of retinopathy of prematurity in extremely premature infants over an 18-year period. Clin Experiment Ophthalmol 2012; 40: 93-99.
31. Zin AA, Moreira ME, Bunce C, Darlow BA, Gilbert CE. Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications. Pediatrics 2010; 126: e410-17.
32. Darlow BA, Zin AA, Beecroft G, Moreira ME, Gilbert CE. Capacity building of nurses providing neonatal care in Rio de Janeiro, Brazil: methods for the POINTS of care project to enhance nursing education and reduce adverse neonatal outcomes. BMC Nurs 2012; 11: 3.
33. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008; 49: 5177-82.
34. Patz A, Hoeck LE, De la Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia, I: nursery observations. Am J Ophthalmol 1952; 35: 1248-53.
35. Ashton N. Pathological basis of retrolental fibroplasia. Br J Ophthalmol 1954; 38: 385-96.
36. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-11.
37. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 2009; 4: 1565-73.
38. Nicolaides KH, Economides DL, Soothill PW. Blood gases, pH, and lactate in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 1989; 161: 996-1001.
39. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin defi ciency decreases vascular stability in mice. J Clin Invest 2008; 118: 526-33.
40. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 1329-35.
41. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-09.
42. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114: 1219-28.
43. Shah PK, Narendran V, Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed 2012; 97: F371-75.
44. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993; 34: 576-85.
45. Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin-like growth factor I defi ciency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016-20.
46. Connor KM, Sangiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 13: 868-73.
47. Pawlik D, Lauterbach R, Turyk E. Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics 2011; 127: 223-28.
48. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-61.
49. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-92.
50. Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res 2009; 28: 452-82.
51. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991; 98: 1628-40.
52. Austeng D, Kallen KB, Hellstrom A, et al. Screening for retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2011; 129: 167-72.
53. Chen ML, Allred EN, Hecht JL, et al. Placenta microbiology and histology and the risk for severe retinopathy of prematurity. Invest Ophthalmol Vis Sci 2011; 52: 7052-58.
54. Bolton DPG, Cross KW. Further observations on cost of preventing retrolental fibroplasia. Lancet 1974; 303: 445-48.
55. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84: F106-10.
56. Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol 2004; 24: 164-68.
57. Sun SC. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res 2002; 51: 350A.
58. Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W. NeOProM: neonatal oxygenation prospective meta-analysis collaboration study protocol. BMC Pediatr 2011; 11: 6.
59. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial I: primary outcomes. Pediatrics 2000; 105: 295-310.
60. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959-67.
61. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 2010; 125: e1483-92.
62. Saito Y, Omoto T, Cho Y, Hatsukawa Y, Fujimura M, Takeuchi T. The progression of retinopathy of prematurity and fl uctuation in blood gas tension. Graefes Arch Clin Exp Ophthalmol 1993; 231: 151-56.
63. Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 1995; 346: 1464-65.
64. York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fl uctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol 2004; 24: 82-87.
65. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994; 36: 724-31.
66. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci 1995; 36: 2063-70.
67. Di Fiore JM, Bloom JN, Orge F, et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010; 157: 69-73.
68. Coleman RJ, Beharry KD, Brock RS, Abad-Santos P, Abad-Santos M, Modanlou HD. Effects of brief, clustered versus dispersed hypoxic episodes on systemic and ocular growth factors in a rat model of oxygen-induced retinopathy. Pediatr Res 2008; 64: 50-55.
69. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003; 111: 339-45.
70. Castillo A, Deulofeut R, Critz A, Sola A. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology. Acta Paediatr 2011; 100: 188-92.
71. The EXPRESS Group. Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS). Acta Paediatr 2010; 99: 978-92.
72. Bardin C, Zelkowitz P, Papageorgiou A. Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. Pediatrics 1997; 100: E4.
73. Regev RH, Lusky A, Dolfi n T, Litmanovitz I, Arnon S, Reichman B. Excess mortality and morbidity among small-for-gestational-age premature infants: a population-based study. J Pediatr 2003; 143: 186-91.
74. Allegaert K, Vanhole C, Casteels I, et al. Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity. J AAPOS 2003; 7: 34-37.
75. Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N. Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 2009; 94: F193-95.
76. Fortes Filho JB, Valiatti FB, Eckert GU, Costa MC, Silveira RC, Procianoy RS. Is being small for gestational age a risk factor for retinopathy of prematurity? A study with 345 very low birth weight preterm infants. J Pediatr (Rio J) 2009; 85: 48-54.
77. Qiu X, Lodha A, Shah PS, et al. Neonatal outcomes of small for gestational age preterm infants in Canada. Am J Perinatol 2012; 29: 87-94.
78. Lassarre C, Hardouin S, Daff os F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991; 29: 219-25.
79. Reece EA, Wiznitzer A, Le E, Homko CJ, Behrman H, Spencer EM. The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 1994; 84: 88-95.
80. Lineham JD, Smith RM, Dahlenburg GW, et al. Circulating insulinlike growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986; 13: 37-46.
81. Larnkjar A, Molgaard C, Michaelsen KF. Early nutrition impact on the insulin-like growth factor axis and later health consequences. Curr Opin Clin Nutr Metab Care 2012; 15: 285-92.
82. Demendi C, Borzsonyi B, Nagy ZB, Rigo J Jr, Pajor A, Joo JG. Gene expression patterns of insulin-like growth factor 1, 2 (IGF-1, IGF-2) and insulin-like growth factor binding protein 3 (IGFBP-3) in human placenta from preterm deliveries: infl uence of additional factors. Eur J Obstet Gynecol Reprod Biol 2012; 160: 40-44.
83. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001; 98: 5804-08.
84. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-09.
85. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-95.
86. Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007; 104: 10589-94.
87. Lofqvist C, Engstrom E, Sigurdsson J, et al. Postnatal head growth defi cit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 defi cit. Pediatrics 2006; 117: 1930-38.
88. Hansen-Pupp I, Hovel H, Hellstrom A, et al. Postnatal decrease in circulating insulin-like growth factor-I and low brain volumes in very preterm infants. J Clin Endocrinol Metab 2011; 96: 1129-35.
89. Gyllensten LJ, Hellstrom BE. Experimental approach to the pathogenesis of retrolental fibroplasia III: changes in the eye induced by exposure of newborn mice to general hypoxia. Br J Ophthalmol 1955; 39: 409-15.
90. Garg R, Agthe AG, Donohue PK, Lehmann CU. Hyperglycemia and retinopathy of prematurity in very low birth weight infants. J Perinatol 2003; 23: 186-94.
91. Ertl T, Gyarmati J, Gaal V, Szabo I. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. Biol Neonate 2006; 89: 56-59.
92. Blanco CL, Baillargeon JG, Morrison RL, Gong AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26: 737-41.
93. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNFa) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
94. Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Niemeyer J, Grunkemeier G. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol 2011; 31: 251-57.
95. Hansen-Pupp I, Lofqvist C, Polberger S, et al. Infl uence of insulin-like growth factor I and nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011; 69: 448-53.
96. Fryklund L, Gluckman P, Skottner A. Treatment of catabolic states using authentic IGF-I and hypocaloric amount of nutrients. US Patent # 6034059. http://patents.com/us-6034059.html (accessed April 3, 2013).
97. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS 2000; 4: 343-47.
98. Hellstrom A, Hard AL, Engstrom E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, effi cient approach to screening. Pediatrics 2009; 123: e638-45.
99. Fortes Filho JB, Bonomo PP, Maia M, Procianoy RS. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol 2009; 247: 831-36.
100. Wu C, Lofqvist C, Smith LE, VanderVeen DK, Hellstrom A, for the WINROP Consortium. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012; 130: 992-99.
101. Mittal M, Dhanireddy R, Higgins RD. Candida sepsis and association with retinopathy of prematurity. Pediatrics 1998; 101: 654-57.
102. Manzoni P, Maestri A, Leonessa M, Mostert M, Farina D, Gomirato G. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol 2006; 26: 23-30.
103. Tolsma KW, Allred EN, Chen ML, Duker J, Leviton A, Dammann O. Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol 2011; 129: 1555-63.
104. Dammann O, Brinkhaus MJ, Bartels DB, et al. Immaturity, perinatal infl ammation, and retinopathy of prematurity: a multi-hit hypothesis. Early Hum Dev 2009; 85: 325-29.
105. Dammann O. Infl ammation and retinopathy of prematurity. Acta Paediatr 2010; 99: 975-77.
106. Sood BG, Madan A, Saha S, et al, for the NICHD neonatal research network. Perinatal systemic infl ammatory response syndrome and retinopathy of prematurity. Pediatr Res 2010; 67: 394-400.
107. Chen M, Citil A, McCabe F, et al. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neonatology 2011; 99: 125-32.
108. Cooke RW, Clark D, Hickey-Dwyer M, Weindling AM. The apparent role of blood transfusions in the development of retinopathy of prematurity. Eur J Pediatr 1993; 152: 833-36.
109. Giannantonio C, Papacci P, Cota F, et al. Analysis of risk factors for progression to treatment-requiring ROP in a single neonatal intensive care unit: is the exposure time relevant? J Matern Fetal Neonatal Med 2012; 25: 471-77.
110. Brooks SE, Marcus DM, Gillis D, Pirie E, Johnson MH, Bhatia J. The effect of blood transfusion protocol on retinopathy of prematurity: a prospective, randomized study. Pediatrics 1999; 104: 514-18.
111. Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr 2013; published online Jan 23. DOI:10.1016/j.jpeds.2012.12.038.
112. Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP). J Biomed Sci 2010; 17: 69.
113. Leviton A, Dammann O, Engelke S, et al. The clustering of disorders in infants born before the 28th week of gestation. Acta Paediatr 2010; 99: 1795-800.
114. Farooqi A, Hagglof B, Sedin G, Serenius F. Impact at age 11 years of major neonatal morbidities in children born extremely preterm. Pediatrics 2011; 127: e1247-57.
115. An international classification of retinopathy of prematurity. Pediatrics 1984; 74: 127-33.
116. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-99.
117. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-94.
118. American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certifi ed Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131: 189-95.
119. Kleberg A, Warren I, Norman E, et al. Lower stress responses after Newborn Individualized Developmental Care and Assessment Program care during eye screening examinations for retinopathy of prematurity: a randomized study. Pediatrics 2008; 121: e1267-78.
120. Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572-76.
121. Lofqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711-18.
122. Wu C, Vanderveen DK, Hellstrom A, Lofqvist C, Smith LE. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128: 443-47.
123. Fluckiger S, Bucher HU, Hellstrom A, Lovqist C, Sturm V, Arri SJ. Der fruhe postnatale Gewichtsverlauf als Pradiktor einer Fruhgeborenenretinopathie. Klin Monbl Augenheilkd 2011; 228: 306-10.
124. Zepeda-Romero LC, Hard AL, Gomez-Ruiz LM, et al. Prediction of retinopathy of prematurity using the screening algorithm WINROP in a Mexican population of preterm infants. Arch Ophthalmol 2012; 130: 720-23.
125. Lofqvist C, Hansen-Pupp I, Andersson E, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009; 127: 622-27.
126. Hard AL, Lofqvist C, Fortes Filho JB, Procianoy RS, Smith L, Hellstrom A. Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol 2010; 128: 1432-36.
127. Binenbaum G, Ying GS, Quinn GE, et al, for the Premature Infants in Need of Transfusion Study Group. A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics 2011; 127: e607-14.
128. Aydemir O, Sarikabadayi YU, Aydemir C, et al. Adjusted poor weight gain for birth weight and gestational age as a predictor of severe ROP in VLBW infants. Eye (Lond) 2011; 25: 725-29.
129. Eckert GU, Fortes Filho JB, Maia M, Procianoy RS. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye (Lond) 2012; 26: 400-06.
130. Salcone EM, Johnston S, VanderVeen D. Review of the use of digital imaging in retinopathy of prematurity screening. Semin Ophthalmol 2010; 25: 214-17.
131. Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: fi nal results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005; 123: 311-18.
132. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity- preliminary results. Arch Ophthalmol 1988; 106: 471-79.
133. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119: 1110-18.
134. Hardy RJ, Palmer EA, Dobson V, et al. Risk analysis of prethreshold retinopathy of prematurity. Arch Ophthalmol 2003; 121: 1697-701.
135. Good WV, Hardy RJ, ETROP Multicenter Study Group. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology 2001; 108: 1013-14.
136. Fielder AR. Premature for life. Arch Ophthalmol 2005; 123: 392-94.
137. Slidsborg C, Forman JL, Fielder AR, et al. Experts do not agree when to treat retinopathy of prematurity based on plus disease. Br J Ophthalmol 2012; 96: 549-53.
138. Shah DN, Wilson CM, Ying GS, et al. Comparison of expert graders to computer-assisted image analysis of the retina in retinopathy of prematurity. Br J Ophthalmol 2011; 95: 1442-45.
139. Wittenberg LA, Jonsson NJ, Paul Chan RV, Chiang MF. Computer-based image analysis for plus disease diagnosis in retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2012; 49: 11-19.
140. Silva RA, Murakami Y, Lad EM, Moshfeghi DM. Stanford University network for diagnosis of retinopathy of prematurity (SUNDROP): 36-month experience with telemedicine screening. Ophthalmic Surg Lasers Imaging 2011; 42: 12-19.
141. Murakami Y, Silva RA, Jain A, Lad EM, Gandhi J, Moshfeghi DM. Stanford University network for diagnosis of retinopathy of prematurity (SUNDROP): 24-month experience with telemedicine screening. Acta Ophthalmol 2010; 88: 317-22.
142. Zepeda-Romero LC, Martinez-Perez ME, Ruiz-Velasco S, Ramirez-Ortiz MA, Gutierrez-Padilla JA. Temporary morphological changes in plus disease induced during contact digital imaging. Eye (Lond) 2011; 25: 1337-40.
143. Singh R, Reddy DM, Barkmeier AJ, Holz ER, Ram R, Carvounis PE. Long-term visual outcomes following lens-sparing vitrectomy for retinopathy of prematurity. Br J Ophthalmol 2012; 96: 1395-98.
144. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996; 114: 417-24.
145. Msall ME, Phelps DL, Hardy RJ, et al, for the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Educational and social competencies at 8 years in children with threshold retinopathy of prematurity in the CRYO-ROP multicenter study. Pediatrics 2004; 113: 790-99.
146. Quinn GE, Dobson V, Saigal S, et al. Health-related quality of life at age 10 years in very low-birth-weight children with and without threshold retinopathy of prematurity. Arch Ophthalmol 2004; 122: 1659-66.
147. Early Treatment for Retinopathy of Prematurity Cooperative Group. Grating visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011; 129: 840-46.
148. Repka MX, Tung B, Good WV, Capone A Jr, Shapiro MJ. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011; 129: 1175-79.
149. Repka MX. Ophthalmological problems of the premature infant. Ment Retard Dev Disabil Res Rev 2002; 8: 249-57.
150. Hansen RM, Harris ME, Moskowitz A, Fulton AB. Deactivation of the rod response in retinopathy of prematurity. Doc Ophthalmol 2010; 121: 29-35.
151. Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM. Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye (Lond) 2010; 24: 14-20.
152. Chen TC, Tsai TH, Shih YF, et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010; 51: 6140-48.
153. VanderVeen DK, Bremer DL, Fellows RR, et al. Prevalence and course of strabismus through age 6 years in participants of the early treatment for retinopathy of prematurity randomized trial. J AAPOS 2011; 15: 536-40.
154. Slidsborg C, Bangsgaard R, Fledelius HC, Jensen H, Greisen G, la Cour M. Cerebral damage may be the primary risk factor for visual impairment in preschool children born extremely premature. Arch Ophthalmol 2012; 130: 1410-17.
155. Wilson DC, Cairns P, Halliday HL, Reid M, McClure G, Dodge JA. Randomised controlled trial of an aggressive nutritional regimen in sick very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1997; 77: F4-11.
156. Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002; 87: 3413-16.
157. Perez-Munuzuri A, Fernandez-Lorenzo JR, Couce-Pico ML, Blanco-Teijeiro MJ, Fraga-Bermudez JM. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr 2010; 99: 519-25.
158. Lofqvist C, Niklasson A, Engstrom E, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res 2009; 65: 574-79.
159. Crawford MA, Golfetto I, Ghebremeskel K, et al. The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants. Lipids 2003; 38: 303-15.
160. Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 2011; 27: 623-27.
161. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Effi cacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-15.
162. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153: 327-33 e1.
163. Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment- A review. Acta Paediatr 2011; 100: 1523-27.
164. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013; 98: F170-74.
165. Hard AL, Hellstrom A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011; 100: 1063-65.
166. Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and effi cacy of propranolol in newborns with retinopathy of prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010; 10: 83.
167. Chen J, Joyal JS, Hatton CJ, et al. Propranolol inhibition of β-adrenergicreceptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2012; 53: 2968-77.
168. Howlett A, Ohlsson A, Plakkal N. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2012; 3: CD000366.
169. Phelps DL, Lakatos L, Watts JL. D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2001; 1: CD001073.
170. Parad RB, Allred EN, Rosenfeld WN, Davis JM. Reduction of retinopathy of prematurity in extremely low gestational age newborns treated with recombinant human Cu/Zn superoxide dismutase. Neonatology 2012; 102: 139-44.
171. Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997; 131: 844-50.